Brandon hahnlen, bs, mba- president/ PRINCIPAL toxicologist

Brandon Hahnlen is President and Principal Toxicologist at Midwest Biocompatibility Consultants. He has spent his entire career within the Medical Device and Medical Research industries in several roles including as a toxicology lab technologist, GLP study director, Analytical Laboratory Management member, GLP Study Director management and most recently Toxicologist/Biocompatibility Subject Matter Expert.  Additionally, he has worked both within the CRO medical device space with extensive time at NAMSA, as well as experience in medical device manufacturing supporting ongoing biocompatibility needs for a global vascular intervention company.

Brandon has extensive experience with the ISO 10993 standard series and its associated testing including: Chemical Characterization (E&L studies), Toxicological Risk Assessment, In Vitro biocompatibility with emphasis on genotoxicity testing, In Vivo biocompatibility testing (both compendial and surgical methods), as well as hemocompatibility testing. With years of GLP Study Director experience with a wide range of complex devices across sub-specialties, Brandon has assisted numerous clients navigate the requirements of several industries' standards including ISO 10993-1, ISO-18652, ISO-11979, and USP <1663>/<1664>.

Brandon received his Bachelor's of Science in Molecular and Cellular Biology, with a minor in Chemistry from Kent State University as well as a MBA from Bowling Green State University Schmidthorst College of Business. Brandon is scheduled to sit for the Diplomat of American Board of Toxicology (DABT) exam in 2023.